Is ALLO or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Hemab Therapeutics N/A N/A N/A

Does the media favor ALLO or COAG?

In the previous week, Hemab Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for Hemab Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 beat Hemab Therapeutics' score of -0.08 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NUVB or ALLO?

In the previous week, Nuvation Bio had 8 more articles in the media than Allogene Therapeutics. MarketBeat recorded 10 mentions for Nuvation Bio and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 beat Nuvation Bio's score of -0.22 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, VCEL or ALLO?

Vericel has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.36 $16.52M $0.47 95.94 Allogene Therapeutics $20K 34,687.58 -$190.89M -$0.77 N/A

Does the media refer more to VCEL or ALLO?

In the previous week, Vericel had 12 more articles in the media than Allogene Therapeutics. MarketBeat recorded 14 mentions for Vericel and 2 mentions for Allogene Therapeutics. Vericel's average media sentiment score of 0.62 beat Allogene Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KLRA or ALLO more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Allogene Therapeutics N/A -56.45% -40.36%

Does the media prefer IOVA or ALLO?

In the previous week, Iovance Biotherapeutics had 25 more articles in the media than Allogene Therapeutics. MarketBeat recorded 27 mentions for Iovance Biotherapeutics and 2 mentions for Allogene Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.40 beat Allogene Therapeutics' score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 5 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Allogene Therapeutics (ALLO) Competitors

$2.01 +0.04 (+2.03%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08/7/2026 07:38 PM Eastern

Compare

ALLO vs. COAG, NUVB, VCEL, KLRA, and IOVA

Should you buy Allogene Therapeutics stock or one of its competitors? MarketBeat compares Allogene Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allogene Therapeutics include Hemab Therapeutics (COAG), Nuvation Bio (NUVB), Vericel (VCEL), Kailera Therapeutics (KLRA), and Iovance Biotherapeutics (IOVA).

How does Allogene Therapeutics compare to Hemab Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Hemab Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for Hemab Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 beat Hemab Therapeutics' score of -0.08 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,687.58	-$190.89M	-$0.77	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

Hemab Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Hemab Therapeutics	N/A	N/A	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Allogene Therapeutics presently has a consensus price target of $8.52, suggesting a potential upside of 323.99%. Hemab Therapeutics has a consensus price target of $48.00, suggesting a potential downside of 3.34%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Allogene Therapeutics beats Hemab Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Allogene Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

In the previous week, Nuvation Bio had 8 more articles in the media than Allogene Therapeutics. MarketBeat recorded 10 mentions for Nuvation Bio and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 beat Nuvation Bio's score of -0.22 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Allogene Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -44.27% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-44.27%	-23.31%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Nuvation Bio currently has a consensus price target of $13.00, suggesting a potential upside of 96.82%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 323.99%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Allogene Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	36.56	-$204.63M	-$0.43	N/A
Allogene Therapeutics	$20K	34,687.58	-$190.89M	-$0.77	N/A

Summary

Allogene Therapeutics beats Nuvation Bio on 9 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Vericel?

Vericel (NASDAQ:VCEL) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

83.6% of Allogene Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vericel had 12 more articles in the media than Allogene Therapeutics. MarketBeat recorded 14 mentions for Vericel and 2 mentions for Allogene Therapeutics. Vericel's average media sentiment score of 0.62 beat Allogene Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Vericel presently has a consensus price target of $58.40, suggesting a potential upside of 29.52%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 323.99%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Vericel has a net margin of 7.91% compared to Allogene Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Vericel has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.36	$16.52M	$0.47	95.94
Allogene Therapeutics	$20K	34,687.58	-$190.89M	-$0.77	N/A

Summary

Vericel beats Allogene Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 129.10%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 323.99%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Kailera Therapeutics has higher earnings, but lower revenue than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Allogene Therapeutics	$20K	34,687.58	-$190.89M	-$0.77	N/A

In the previous week, Allogene Therapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 2 mentions for Allogene Therapeutics and 1 mentions for Kailera Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 beat Kailera Therapeutics' score of -1.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kailera Therapeutics	Negative
Allogene Therapeutics	Neutral

83.6% of Allogene Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kailera Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

Allogene Therapeutics beats Kailera Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Allogene Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Iovance Biotherapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Allogene Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$324.97M	8.71	-$390.98M	-$0.73	N/A
Allogene Therapeutics	$20K	34,687.58	-$190.89M	-$0.77	N/A

Allogene Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.92% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.92%	-31.66%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Iovance Biotherapeutics presently has a consensus price target of $8.00, indicating a potential upside of 26.18%. Allogene Therapeutics has a consensus price target of $8.52, indicating a potential upside of 323.99%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Iovance Biotherapeutics had 25 more articles in the media than Allogene Therapeutics. MarketBeat recorded 27 mentions for Iovance Biotherapeutics and 2 mentions for Allogene Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.40 beat Allogene Therapeutics' score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	5 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Allogene Therapeutics beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLO vs. The Competition

Export

Metric	Allogene Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$679.96M	$3.62B	$6.92B	$12.86B
Dividend Yield	N/A	3.77%	2.59%	9.91%
P/E Ratio	-2.61	9.07	271.66	25.24
Price / Sales	34,687.58	1,285.19	600.80	98.85
Price / Cash	N/A	98.58	71.46	49.72
Price / Book	1.55	18.10	13.25	6.22
Net Income	-$190.89M	-$13.25M	$3.45B	$342.66M
7 Day Performance	6.91%	6.24%	4.67%	4.41%
1 Month Performance	-5.19%	-2.70%	-0.79%	-0.28%
1 Year Performance	93.27%	61.17%	76.94%	22.60%

Allogene Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLO Allogene Therapeutics	1.8555 of 5 stars	$2.01 +2.0%	$8.52 +324.0%	+91.4%	$679.96M	$20K	N/A	310	Positive News Upcoming Earnings
COAG Hemab Therapeutics	2.0501 of 5 stars	$50.39 +6.5%	$48.00 -4.7%	N/A	$2.35B	N/A	N/A	72
NUVB Nuvation Bio	3.1381 of 5 stars	$6.65 +3.5%	$12.88 +93.8%	+182.9%	$2.32B	$143.05M	N/A	60	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up
VCEL Vericel	4.1531 of 5 stars	$45.32 +0.6%	$55.50 +22.5%	+24.7%	$2.30B	$276.26M	107.91	300	Analyst Revision
KLRA Kailera Therapeutics	2.7745 of 5 stars	$17.48 -1.2%	$42.75 +144.6%	N/A	$2.29B	N/A	N/A	145

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Competitors

ALLO vs. COAG, NUVB, VCEL, KLRA, and IOVA

How does Allogene Therapeutics compare to Hemab Therapeutics?

Summary

How does Allogene Therapeutics compare to Nuvation Bio?

Summary

How does Allogene Therapeutics compare to Vericel?

Summary

How does Allogene Therapeutics compare to Kailera Therapeutics?

Summary

How does Allogene Therapeutics compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Competitors

ALLO vs. COAG, NUVB, VCEL, KLRA, and IOVA

How does Allogene Therapeutics compare to Hemab Therapeutics?

Does the media favor ALLO or COAG?

Which has higher earnings & valuation, ALLO or COAG?

Is ALLO or COAG more profitable?

Do insiders & institutionals have more ownership in ALLO or COAG?

Do analysts recommend ALLO or COAG?

Summary

How does Allogene Therapeutics compare to Nuvation Bio?

Which has more risk & volatility, NUVB or ALLO?

Does the media refer more to NUVB or ALLO?

Do institutionals & insiders hold more shares of NUVB or ALLO?

Is NUVB or ALLO more profitable?

Do analysts recommend NUVB or ALLO?

Which has better valuation and earnings, NUVB or ALLO?

Summary

How does Allogene Therapeutics compare to Vericel?

Do institutionals and insiders have more ownership in VCEL or ALLO?

Does the media refer more to VCEL or ALLO?

Which has more risk & volatility, VCEL or ALLO?

Do analysts prefer VCEL or ALLO?

Is VCEL or ALLO more profitable?

Which has higher valuation & earnings, VCEL or ALLO?

Summary

How does Allogene Therapeutics compare to Kailera Therapeutics?

Do analysts prefer KLRA or ALLO?

Which has higher valuation and earnings, KLRA or ALLO?

Does the media favor KLRA or ALLO?

Do institutionals and insiders hold more shares of KLRA or ALLO?

Is KLRA or ALLO more profitable?

Summary

How does Allogene Therapeutics compare to Iovance Biotherapeutics?

Which has more risk and volatility, IOVA or ALLO?

Do insiders & institutionals have more ownership in IOVA or ALLO?

Which has stronger valuation & earnings, IOVA or ALLO?

Is IOVA or ALLO more profitable?

Do analysts recommend IOVA or ALLO?

Does the media prefer IOVA or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools